FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013164041> ?p ?o ?g. }

• W2013164041 endingPage "603" @default.
• W2013164041 startingPage "594" @default.
• W2013164041 abstract "HomeCirculation: Arrhythmia and ElectrophysiologyVol. 5, No. 3Basic Science of Cardiac Resynchronization Therapy Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessResearch ArticlePDF/EPUBBasic Science of Cardiac Resynchronization TherapyMolecular and Electrophysiological Mechanisms Hana Cho, MD, PhD, Andreas S. Barth, MD, PhD and Gordon F. Tomaselli, MD Hana ChoHana Cho Search for more papers by this author , Andreas S. BarthAndreas S. Barth Search for more papers by this author and Gordon F. TomaselliGordon F. Tomaselli Search for more papers by this author Originally published1 Jun 2012https://doi.org/10.1161/CIRCEP.111.962746Circulation: Arrhythmia and Electrophysiology. 2012;5:594–603IntroductionElectromechanical dyssynchrony can markedly worsen heart failure (HF) morbidity and mortality, independent of traditional risk factors.1–4 Depending on the metric used, current estimates of the prevalence of dyssynchrony vary from 25–30% in patients with HF (based on QRS widening) up to 60%, based on tissue Doppler or MRI measures of dyssynchronous contraction of the left ventricle (LV).5,6 Cardiac resynchronization therapy (CRT) or biventricular pacing has emerged as a promising option to treat patients with HF and dyssynchronous contraction.7–9 The past few decades have seen the rise of pharmacotherapy, primarily through agents that antagonize the effect of excessive concentrations of circulating neurohormones, yet, HF-related morbidity and mortality remain high.3–6 Biventricular stimulation has been demonstrated to improve contractile performance in patients with mechanical dyssynchrony acutely and chronically while also prolonging long-term survival—something not yet achieved by drug therapy.10 Although the clinical and mechanical effectiveness of CRT are well described, 30% of patients do not benefit from CRT and clinical criteria to identify CRT nonresponders remain elusive8,11,12 Currently, the most widely used predictor of reverse remodeling is the presence of marked mechanical dyssynchrony before CRT, as indexed by the width of the QRS.13 Mechanical dyssynchrony seems important, yet imaging-based measures have not predicted response well14 and even improvement in dyssynchrony after initiation of CRT only weakly predicts chronic response.15 Limited understanding of the molecular mechanisms underlying reverse cardiac remodeling induced by CRT has hampered the selection of potential responders. In this review, we focus on the electrophysiological aspects and molecular networks underlying the benefits of CRT. We will review how CRT homogenizes regional differences in stress kinase signaling and electric remodeling and then review its global effect on myocyte function and its broader impact on the cardiac ventricular transcriptome. A comprehensive understanding of the molecular features of dyssynchronous contraction in the failing heart (DHF) and its reversibility by biventricular pacing promises to identify sets of biological markers for the selection of patients who will benefit most from CRT and, in a more general sense, to advance our knowledge of HF-associated pathophysiological processes.Beyond the Mechano-EnergeticsUntil recently, the prevailing view of CRT efficacy is that it reduces mechanical inefficiency from discoordinate contraction, allowing more blood to be ejected at a lower energy cost. Multisite ventricular pacing had been proposed for ventricular arrhythmia termination and ultimately for improvement in hemodynamic performance in patients with HF.16 CRT was developed in the mid-1990s after investigators found that biventricular (or LV only) preexcitation could restore mechanical synchrony and improve acute LV mechanics,17 energetic efficiency,18 and regional metabolism.19 Subsequent large-scale clinical trials demonstrated that CRT can acutely and chronically enhance cardiac work and systolic performance in selected patients.7,20,21 Using a canine model of dyssynchronous ventricular contraction, our group has corroborated the mechanical benefits of CRT. Dogs treated with biventricular rapid pacing after an initial period of dyssynchronous HF of 3 weeks had a slight but significant improvement in ejection fraction and stroke volume, whereas both ejection fraction and stroke volume continued to decline in dogs with continued HF with dyssynchronous contraction (DHF) (Figure 1A).22 In this model, resynchronization of LV contraction was confirmed by MRI circumferential uniformity ratio estimate (CURE) index or standard tissue Doppler parameters (Figure 1B). The observed improvement of myocardial function in both animal models and HF patients raised the question of whether wall motion is all there is to LV preexcitation, or whether effective CRT might also reverse cellular remodeling. In fact, another mechanical circulatory support mechanism, LV assist devices are known to induce myocardial changes at the cellular and structural level such that a small number of patients may recover sufficient cardiac function that permits device removal.23–25 Hints at changes in cellular signaling pathways by CRT first came from human studies of responders versus “nonresponders,” where myocardial gene expression changes of calcium handling proteins, β-receptors, and natriuretic peptides were reversed preferentially in responders.26–28 Patients with effective CRT display chronic enhancement of circulating apelin, a secreted hormone that can block adverse remodeling and has positive inotropic effects.29 Circulating biomarkers of extracellular matrix remodeling also accompanies successful CRT, including decreases in tenascin-C, and matrix metalloproteinase 9.30 Chronic CRT also has anti-inflammatory effects and reduces monocyte chemoattractant protein-1, interleukin-8, and interleukin-6 levels.31 Although these studies do not identify the underlying mechanisms by which CRT exerts its beneficial effect, they may suggest biomarkers for therapies that both enhance systolic function and survival in HF patients.Download figureDownload PowerPointFigure 1. Development of a canine model of cardiac dyssynchrony and resynchronization. In this model, both dyssynchronous heart failure (DHF) and resynchronized heart failure [cardiac resynchronization therapy (CRT)] groups are exposed first to tachypacing for 3 weeks (in the presence of a preestablished left bundle-branch block). This protocol is continued for an additional 3 weeks in DHF hearts but is switched to rapid biventricular pacing in CRT hearts. A, Left ventricular dyssynchrony (DI, left) is assessed by the variance in timing delay in systolic motion using tissue Doppler. This is similar in both groups at 3 weeks and declines to control levels (synchrony) only in the CRT group. Slight improvements in ejection fraction (EF, middle) and stroke volume (SV, right) are noted in the CRT group but not in the DHF group at 6 weeks. B, Myocardial strain patterns (tissue Doppler images) obtained in the anterior and lateral wall (tissue Doppler) from a normal control, DHF heart, and CRT heart. With DHF, major disparities in the timing of shortening and reciprocal shortening/stretch in each region are ameliorated by CRT. Adapted from Chakir et al.22Regional Molecular Changes in HF and CRTStress Response KinasesInitial molecular insights into DHF were provided in a report by our group32 examining the regional effects of DHF on molecular signaling. This study revealed the selective downregulation of Ca2+ handling proteins and connexin 43 and upregulation of mitogen-activated protein kinase in the lateral wall only, referred to as molecular polarization. This regional molecular change was not observed in synchronous HF. In a more recent study by Chakir et al,33 the lateral wall of DHF ventricles exhibited an increase in p38 MAPK and Ca2+-calmodulin kinase II (CaMKII) activation and increased tumor necrosis factor (TNF)-α expression, which were both reversed by CRT (Figure 2). These localized differences in stress kinase activation were consistent with disparities in regional work load in DHF and its equalization by CRT (Figure 1). The changes in stress response kinases are potentially important, given the impact of these proteins on muscle function, survival, and fibrosis. P38 MAPK stimulates fibrosis and apoptosis and is associated with contractile failure.34,35 CaMKII is an important mediator of β-adrenergic–related toxicity leading to apoptosis,36 cardiac hypertrophy,37,38 and the generation of cardiac arrhythmias.39,40 TNF-α stimulates fibrosis and apoptosis, and overexpression induces dilated cardiomyopathy.41 Expression TNF-α can be triggered by abnormal mechanical loading,42 and its decline solely in the lateral wall of CRT hearts supports this mechanism. This change is also supported by recent human data reporting lower levels of LV TNF-α after 6 months of CRT.43Download figureDownload PowerPointFigure 2. Cardiac resynchronization therapy (CRT) reverses regional disparities in activation of stress response kinases. Summarized data for activity and expression of p38 MAPK, CaMKII, and TNF-α show relative increases in lateral wall in DHF hearts that are reversed by CRT. Adapted from Chakir et al.33Electrophysiological Changes in DHF and CRTIn addition to molecular polarization, DHF is characterized by regional heterogeneities in cellular and tissue electrophysiological properties. The hallmark signature of cells and tissues isolated from failing hearts, independent of the etiology, is action potential (AP) prolongation.44–50 AP prolongation in DHF is most prominent in cells isolated from the late-activated lateral LV wall and is an index of the exaggeration of the physiological heterogeneity of electric properties in the failing heart.51 CRT significantly shortens the AP in lateral myocytes and thus reduces LV regional heterogeneity in action potential duration (APD) (Figure 3). Regional alterations in ionic currents underlie the AP remodeling; however, the molecular mechanisms of regional ionic current remodeling in DHF and CRT are controversial. A prominent increase of TNF-α and CaMKII in the lateral wall might play a role in regional AP remodeling. TNF-α decreases the transient outward potassium current (Ito) and prolongs the APD in rat ventricular myocytes.52 Recently, Xie et al53 suggested that increased oxidative stress in HF activates CaMKII and triggers ventricular arrhythmias. CaMKII modulates Ca2+ currents, sarcoplasmic reticulum (SR) function,54,55 and increases persistent Na+ current,56,57 resulting in prolongation of APD.58 It is possible and indeed likely that other regional alterations in Ca2+ handling or increased persistent Na+ current contribute to regional differences in the APD and AP profile in DHF, and the regionally specific effects of biventricular pacing on this phenotype.Download figureDownload PowerPointFigure 3. Action potential duration (APD) in left ventricular myocytes from control, dyssynchronous heart failure (DHF), and cardiac resynchronization therapy (CRT) hearts. A, Representative superimposed APs recorded at pacing cycle lengths (CL) of 0.5, 1.0, 2.0, and 4.0 seconds. B, Relationship between pacing CL and APD at 90% recovery (APD90) from anterior and lateral myocytes in each group. †P<0.05 versus control; #P<0.05 versus DHF; *P<0.05 versus anterior. Adapted from Aiba et al.51Effects of DHF and CRT on the Regional LV TranscriptomeIn previous studies, we demonstrated that CRT can reverse the regional heterogeneities of electric remodeling and stress response kinases. However, this may be just the tip of iceberg because most analyses were focused on individual proteins and most likely missed a broader impact of dyssynchrony and CRT on regional molecular expression patterns. To test this hypothesis, we used a global gene expression profiling approach in the aforementioned canine model of dyssynchronous HF and CRT that allowed us to examine mRNA expression in anterior and lateral LV myocardium. As aresult of this unbiased and global assessment of transcriptional activity, we identified more than 6 times as many genes to be differentially expressed between nonfailing and DHF hearts in anterior compared with lateral LV myocardium of the same hearts (2173 versus 346 transcripts, respectively; false discovery rate <5%).59 We found prominent downregulation of metabolic pathways (oxidative phosphorylation, fatty acid, amino acid, and glucose metabolism), whereas various cell-signaling pathways were upregulated (MAPK, JAK-STAT, TGF-β) in the anterior LV wall of the dyssynchronous failing heart. The greater downregulation of metabolic transcripts in anterior compared with lateral LV regions is also in good agreement with human studies: using gated PET with 18F-fluorodeoxyglucose and 99mTc-sestamibi single-photon emission-computed tomography to noninvasively measure myocardial glucose metabolism and myocardial perfusion, respectively, Nowak et al19 found that glucose metabolism is reduced more than perfusion in the anteroseptal compared with LV lateral wall in patients with DCM and left bundle-branch block.Importantly, the disparity in the number of regulated transcripts between the early- and late-activated LV regions gave rise to an increased regional heterogeneity of gene expression within the dyssynchronously contracting LV myocardium. These dyssynchrony-induced regional gene expression changes were reversed by CRT to levels comparable to nonfailing hearts (Figure 4). Experimentally, this has been shown to couple with rebalancing of glucose metabolism19 and myocardial blood flow60 (rising in the anterior and declining in lateral walls), and such findings are consistent with CRT-associated increases in transcripts levels encoding oxidative phosphorylation and various metabolic pathways in anterior samples. Our results indicate that by recoordinating contraction, regional heterogeneity of gene expression can be essentially returned to normal, even in a failing heart, on a genome-wide level.Download figureDownload PowerPointFigure 4. Dyssynchrony leads to increased regional heterogeneity in gene expression within the left ventricle that is partially reduced with cardiac resynchronization therapy (CRT). A, Unsupervised clustering of differentially expressed transcripts identified by multiclass Significance Analysis of Microarrays (SAM, false discovery rate <5%) using Euclidean distance for 1-color microarray data shows that transcript expression from CRT hearts clusters with nonfailing (NF) hearts rather than with dyssynchronous heart failure (DHF) samples. Each row represents data for 1 gene. The gene expression level is color-coded with yellow and blue, representing low and high expression, respectively. The difference in gene expression between the anterior and lateral wall from the same heart was compared for NF, DHF, and CRT. B, Pseudoimages of representative microarrays from NF, DHF, and CRT hearts with 211 columns and 206 rows (44K array). RNA from the anterior and lateral regions was labeled with Cy3 and Cy5 and hybridized in a 2-color design onto 1 array. Red and green dots represent statistically significant transcripts between anterior and lateral wall, respectively. C, Bar plot of the number of deregulated genes comparing the anterior and lateral regions in NF, DHF, and CRT hearts. In DHF, the number of differentially expressed transcripts between anterior and lateral wall increases 4-fold, whereas it is greatly reduced by CRT (modified from Barth et al59).Global Effects of CRT on Myocyte FunctionIn addition to reversing regional molecular polarization, CRT globally corrects electrophysiological abnormalities and improves β-adrenergic responsiveness and mitochondrial energetic efficiency. All these changes may play an important role in the ability of CRT to enhance the systolic work performance of the failing heart acutely and chronically while also improving long-term survival.CRT Reverses K+ Channel Remodeling and Reduces AfterdepolarizationsDownregulation of K+ currents is the most consistent ionic current change in animal models47,49,50,61 and human HF.45 K+ current downregulation may promote ventricular tachycardia/ventricular fibrillation50 either by direct prolongation of AP44 in the voltage range at which ICa,L reactivation occurs, predisposing to the development of early afterdepolarizations,62 or by heterogeneously reducing repolarization reserve and promoting functional reentry.63 CRT dramatically reduces the frequency of early afterdepolarizations in cells isolated from both the anterior and lateral LV (Figure 5A and B).Download figureDownload PowerPointFigure 5. Cardiac resynchronization therapy (CRT) reverses K+ channel remodeling and reduces early afterdepolarization (EADs). A, Representative superimposed action potentials (APs) recorded in myocytes isolated from the lateral wall of dyssynchronous heart failure (DHF) hearts with EADs. B, Bar plot of frequency of EADs (%EADs indicates fraction of APs with EADs). C through E, DHF significantly reduces the inward rectifier IK1, the delayed rectifier (IK) and transient outward K+ currents (Ito) in both anterior and lateral cells. CRT partially restores the DHF-induced reduction of IK1 and IK, but not Ito in both anterior and lateral cells. F, Changes in steady-state K+ channel mRNA subunit and protein expression. ANT or A indicates anterior; LTR or L, lateral. Modified from Aiba et al.51We recently reported on these modifications in more detail, revealing that DHF significantly reduced the inward rectifier (IK1), delayed rectifier (IK), and transient outward potassium currents (Ito) in both anterior and lateral myocytes.51 CRT restored DHF-induced K+ current reductions throughout the ventricle, with the exception of Ito (Figure 5C through 5E). In fact, K+ channels are the most diverse class of ion channels. The detailed changes in K+ channels vary with the model of HF or with species.64 Ito is unique among regulated K+ currents in HF because it is downregulated uniformly in HF45–47,50,65 yet not reversed by CRT (Figure 5C).51 In parallel, Kv4.3 and KChIP2 mRNA and protein expression are downregulated in DHF without restoration by CRT (Figure 5F).51IK1 (Kir 2 family of genes) maintains the resting membrane potential and contributes to terminal repolarization. Reduced inward IK1 density in HF46,49,66,67 may contribute to prolongation of APD and enhanced susceptibility to spontaneous depolarizations including delayed afterdepolarizations (DADs).67,68 CRT, even in the setting of continued HF, partially restores IK1 density (Figure 5D),51 decreases membrane resistance, and, in the setting of improved Ca2+ handling in CRT (see below), may reduce the frequency of arrhythmogenic DADs. Kir2.1 mRNA and protein levels are partially restored by CRT in the canine model (Figure 5F).51IK plays a prominent role in the late phase of repolarization69; therefore changes in either the slow (IKs) or fast (IKr) activating components of this current could contribute significantly to AP prolongation in HF. CRT partially restores DHF-induced downregulation of IK density in both anterior and lateral LV myocytes without a significant change in mRNA or protein levels of KvLQT1 or mink subunits for IKs, whereas mRNA level of ERG, a subunit of IKr, was restored by CRT in both the anterior or lateral LV wall (Figure 5E and F).51Ca2+ Handling in DHF and CRTHF is associated with major changes in Ca2+ handling, which underlies the observed reduction in force of contraction of the failing heart. Consistent with this HF phenotype, myocytes isolated from DHF hearts showed calcium transients with a markedly reduced peak amplitude and slowed kinetics51,70 in both the anterior and lateral wall (Figure 6A). CRT dramatically restored both the amplitude and kinetics of the Ca2+ transient. This result is striking, recalling that our CRT model involves 6 weeks of tachypacing, and CRT and DHF hearts have a similar degree of LV dilation and elevation of end-diastolic pressure.Download figureDownload PowerPointFigure 6. Cardiac resynchronization therapy (CRT) restores dyssynchronous heart failure (DHF)-induced reduction in Ca2+ currents (ICa,L) and transients (CaT). A, Compared with the control, DHF significantly reduced the CaT amplitude and slowed the rate of decay of the transient in both anterior and lateral myocytes. CRT partially restored the CaT amplitude of lateral cells and hastened the slowed decay of the CaT in anterior cells. B, In DHF, the peak ICa,L density was smaller and the decay was slower in the lateral myocytes, whereas the peak current density was larger and decay was faster in the anterior myocytes. The reduced current density is observed over a wide range of activation voltages. CRT restored the peak ICa,L density in lateral cells, but the decay was still slow. NF indicates nonfailing C, Summary of the mRNA and protein changes by RT PCR and Western blotting, respectively, in DHF and CRT hearts compared with nonfailing controls. Modified from Aiba et al.51On a beat-by-beat basis, the Ca2+ transient is elicited by the influx of a small amount of Ca2+ through L-type Ca2+ currents (ICa,L) and the subsequent large-scale Ca2+ release from the SR through the ryanodine receptor (RyR2). During diastole, cytosolic Ca2+ is taken up into the SR by the phospholamban (PLN)-regulated SR Ca2+-ATPase (SERCA2A). In DHF, we found that the reduction of ICa,L and Ca2+ transients is more pronounced in the lateral wall versus the anterior wall. Importantly, CRT restored the DHF-induced reduction of peak ICa,L density, thus eliminating the anterior-lateral ICa,L density gradient (Figure 6B).51 However, no significant differences in CaV1.2 (CaVα1C) mRNA and protein or CaVβ1 subunit mRNA expression were found among control, DHF, and CRT hearts (Figure 6C).51 Yet, CaVβ2 mRNA was decreased significantly in DHF but not in CRT myocytes when compared with nonfailing myocardium.51We further tested for the molecular basis of changes in the Ca2+ transient. We found that mRNA and protein levels of SERCA2A, PLN, and RyR2 were downregulated and Na+/Ca2+ exchanger (NCX1) upregulated without a change in CRT (Figure 6C). There were also no regional differences in mRNA and protein expression in any of these mediators of Ca2+ handling in DHF and CRT. These results suggest that the differences of Ca2+ handling in DHF and its restoration by CRT are posttranslational.Rest and β-Adrenergic–Stimulated Myocyte ContractilityThe first hint of a positive impact of CRT on cardiac β-signaling was provided by clinical studies demonstrating reduced muscle sympathetic nerve activity in patients with severe HF and dyssynchrony71 and CRT-mediated enhanced neural norepinephrine reuptake and retention.72 To more directly study myocyte β-adrenergic signaling, our group measured sarcomere shortening after administration of isoproterenol.22 Consistent with many models of HF, DHF myocytes displayed highly blunted contractility at rest and during stimulation with isoproterenol compared with myocytes from nonfailing hearts. Both basal and isoproterenol-stimulated cell shortening were markedly improved by CRT throughout the ventricles, and their recovery was well correlated with an increase in the amplitude and hastening of the kinetics of the Ca2+ transients (Figure 7A).22Download figureDownload PowerPointFigure 7. Cardiac resynchronization therapy (CRT) improves rest and β-adrenergic responsiveness in isolated myocytes from both early and late activated regions. A, Representative tracings of sarcomere length (top traces) and whole-cell calcium transients (Fura2-AM; bottom traces) for myocytes isolated from anterior versus lateral walls from control, dyssynchronous heart failure (DHF), and CRT left ventricles. Baseline and results with isoproterenol (ISO) stimulation are shown. Compared with controls, DHF cells displayed marked depression of resting function and calcium transients, and the ISO response of both was very blunted. Rest and β-adrenergic-stimulated shortening and calcium transients were strikingly improved by CRT. B, DHF results in enhanced inhibitory G-protein (Gi) coupling in DHF myocytes that is absent in CRT. In DHF, pretreatment with the Gi inhibitor pertussis toxin (PTX) enhanced ISO-stimulated contraction, whereas CRT myocytes had enhanced shortening without ISO and showed no further increase with addition of PTX. C, Summarized data for upregulation and downregulation of the regulator of G-protein signaling (RGS) proteins by CRT; → indicates no change; ↓, decreased; and ↑, increased. Adapted from Chakir et al.22We examined the underlying mechanisms for enhanced β-adrenergic responsiveness by CRT. Both β1- and β2-receptor gene expression and receptor number were depressed by DHF, and CRT enhanced β1- but not β2-receptor number, as in humans.73 Functional analysis of adenylyl cyclase activity revealed that it was also depressed by DHF, and CRT augmented cAMP production. Among the most striking changes, however, was inhibitory G-protein (Gi)-coupled signaling. As shown in Figure 7B, myocytes from DHF hearts showed marked potentiation of the isoproterenol response if the myocytes were first incubated with pertussis toxin, which inhibits Gi. In contrast, CRT myocytes displayed enhanced responses at baseline and showed no effect with pertussis toxin, as if Gi already was inhibited by CRT. Consistent with human HF, Giα was upregulated in both DHF and CRT animals and can therefore by itself not account for the enhanced β-adrenergic responsiveness with CRT. However, we found selective upregulation of proteins called regulators of G-protein signaling (RGS) (Figure 7C). RGS proteins negatively regulate G-coupled signaling by acting as selective GTPase accelerators, removing GTP from the activated α-subunit and allowing the trimeric G-protein complex to reform suppressing G-protein–coupled signaling. RGS3, a protein known to suppress Gi, was selectively upregulated in human CRT responders as well as canine models of resynchronization. Moreover, CRT appeared to improve contraction through RGS-mediated enhancement in coupling of β2-adrenergic receptors to stimulatory G-proteins (Gαs).74 Activation of the β2-Gαs axis may represent a general strategy to improve functional reserve in patients with HF and dyssynchronous contraction, perhaps even those who do not respond to CRT.Cell Survival SignalingAs reported both in humans43 and in our canine model,33 DHF hearts display an increase in apoptosis. In the canine pacing tachycardia model, this was supported by TUNEL staining, caspase-3 activity, and nuclear poly ADP-ribose polymerase cleavage. Importantly, apoptosis was suppressed by CRT. One of the most striking changes was a marked decline in Akt phosphorylation/activity with DHF that was also reversed by CRT (Figure 8). Akt is generally considered a prosurvival kinase, and Akt phosphorylation of the proapoptotic protein BAD results in the interaction of BAD with the chaperone 14–3–3, reducing apoptosis. In the canine model, we observed reduced BAD phosphorylation (and 14–3–3 interaction) with DHF, a finding that was reversed with CRT. The antiapoptotic impact of CRT appears to be global in nature, as molecular changes in BAD and 14–3–3 were observed in both anterior and lateral LV myocardium. There are many other factors that regulate cell survival signaling that may also be modified by CRT. The mechanism by which the loss of dyssynchrony reactivates Akt to modify its downstream protein targets such as BAD remains unknown. It is unlikely that improved LV function, which is modest in this model with CRT, accounts for the changes in Akt signaling. However, activation of secreted factors coupled to the abnormal mechanical loading may prove an important pathway, and this is currently being explored.Download figureDownload PowerPointFigure 8. Schema of mitochondrial protein changes with cardiac resynchronization therapy. The pI indicates observed pI differs >1 pH unit from predicted; MW, observed MW differs more than 10 kDa from predicted one. FAD indicates flavin-adenine dinucleotide; FADH2, flavin-adenine dinucleotide, reduced form; NAD+, oxidized nicotinamide-adenine dinucleotide; Pi, inorganic phosphate; and TCA, tricarboxylic acid. Adapted from Agnetti et al.75CRT and MitochondriaGiven the central role of mitochondria in apoptosis pathways, the improved survival signaling prompted us to test the hypothesis that mitochondrial function was favorably altered by CRT. Agnetti et al75 compared changes in mitochondrial protein expression and posttranslational modification between DHF and CRT animals in lateral LV myocardium, demonstrating salutary effects on mitochondrial respiration and efficiency of oxidative phosphorylation with CRT. Using optimized 2D electrophoresis of the mitochondrial subproteome, ≈1200 protein spots were resolved, revealing 31 quantitative protein changes between DHF and CRT. Most changes were in proteins of the respiratory chain, including all of the complexes of oxidative phosphorylation (except complex IV; Figure 8), consistent with CRT modulating ATP production.75 CRT also increased the metabolic pathways supplying the substrates (pyruvate carboxylase and pyruvate dehydrogenase, E1 and E2 subunits) and key enzymes (aldehyde dehydrogenase, α-keto acid dehydrogenase E2, and ferredoxin reductase) fuelling the Krebs cycle. Importantly, mitochondrial oxidative efficiency (ADP/O2) was depressed by DHF and enhanced by CRT. CRT also reduced oxidative stress, potentially by enhanced mitochondrial reactive oxygen species–scavenging proteins. These mitochondrial changes have not been reported with other HF therapies, and may represent a selective response to CRT.ConclusionsWe and others have" @default.
• W2013164041 created "2016-06-24" @default.
• W2013164041 creator A5004295906 @default.
• W2013164041 creator A5009404984 @default.
• W2013164041 creator A5016686582 @default.
• W2013164041 date "2012-06-01" @default.
• W2013164041 modified "2023-09-27" @default.
• W2013164041 title "Basic Science of Cardiac Resynchronization Therapy" @default.
• W2013164041 cites W109933015 @default.
• W2013164041 cites W1600309003 @default.
• W2013164041 cites W1969575386 @default.
• W2013164041 cites W1973349963 @default.
• W2013164041 cites W1981628050 @default.
• W2013164041 cites W1986750147 @default.
• W2013164041 cites W1988005892 @default.
• W2013164041 cites W1988452782 @default.
• W2013164041 cites W1988995152 @default.
• W2013164041 cites W1991902077 @default.
• W2013164041 cites W1996813777 @default.
• W2013164041 cites W2001261561 @default.
• W2013164041 cites W2014165069 @default.
• W2013164041 cites W2024287748 @default.
• W2013164041 cites W2028452724 @default.
• W2013164041 cites W2029159195 @default.
• W2013164041 cites W2032661630 @default.
• W2013164041 cites W2033940966 @default.
• W2013164041 cites W2035667813 @default.
• W2013164041 cites W2037506358 @default.
• W2013164041 cites W2038769531 @default.
• W2013164041 cites W2050624124 @default.
• W2013164041 cites W2051435139 @default.
• W2013164041 cites W2054881768 @default.
• W2013164041 cites W2061256381 @default.
• W2013164041 cites W2061423391 @default.
• W2013164041 cites W2063346793 @default.
• W2013164041 cites W2070551632 @default.
• W2013164041 cites W2074520685 @default.
• W2013164041 cites W2076649159 @default.
• W2013164041 cites W2084265884 @default.
• W2013164041 cites W2084275033 @default.
• W2013164041 cites W2087122238 @default.
• W2013164041 cites W2090164672 @default.
• W2013164041 cites W2099831985 @default.
• W2013164041 cites W2100056258 @default.
• W2013164041 cites W2105658413 @default.
• W2013164041 cites W2108383919 @default.
• W2013164041 cites W2110229985 @default.
• W2013164041 cites W2113111385 @default.
• W2013164041 cites W2117179977 @default.
• W2013164041 cites W2123912993 @default.
• W2013164041 cites W2125007011 @default.
• W2013164041 cites W2128960558 @default.
• W2013164041 cites W2129090778 @default.
• W2013164041 cites W2129900483 @default.
• W2013164041 cites W2130531405 @default.
• W2013164041 cites W2130907431 @default.
• W2013164041 cites W2137116805 @default.
• W2013164041 cites W2139556153 @default.
• W2013164041 cites W2142432219 @default.
• W2013164041 cites W2143679973 @default.
• W2013164041 cites W2144975424 @default.
• W2013164041 cites W2152641257 @default.
• W2013164041 cites W2153077055 @default.
• W2013164041 cites W2154637999 @default.
• W2013164041 cites W2155032388 @default.
• W2013164041 cites W2155154270 @default.
• W2013164041 cites W2155452355 @default.
• W2013164041 cites W2164030561 @default.
• W2013164041 cites W2165620104 @default.
• W2013164041 cites W2167646683 @default.
• W2013164041 cites W2167840127 @default.
• W2013164041 cites W2168269637 @default.
• W2013164041 cites W2171728648 @default.
• W2013164041 cites W2402343679 @default.
• W2013164041 cites W3144470180 @default.
• W2013164041 cites W4229759864 @default.
• W2013164041 cites W4361868645 @default.
• W2013164041 doi "https://doi.org/10.1161/circep.111.962746" @default.
• W2013164041 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3422751" @default.
• W2013164041 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22715238" @default.
• W2013164041 hasPublicationYear "2012" @default.
• W2013164041 type Work @default.
• W2013164041 sameAs 2013164041 @default.
• W2013164041 citedByCount "25" @default.
• W2013164041 countsByYear W20131640412013 @default.
• W2013164041 countsByYear W20131640412014 @default.
• W2013164041 countsByYear W20131640412015 @default.
• W2013164041 countsByYear W20131640412016 @default.
• W2013164041 countsByYear W20131640412017 @default.
• W2013164041 countsByYear W20131640412018 @default.
• W2013164041 countsByYear W20131640412019 @default.
• W2013164041 countsByYear W20131640412022 @default.
• W2013164041 countsByYear W20131640412023 @default.
• W2013164041 crossrefType "journal-article" @default.
• W2013164041 hasAuthorship W2013164041A5004295906 @default.
• W2013164041 hasAuthorship W2013164041A5009404984 @default.
• W2013164041 hasAuthorship W2013164041A5016686582 @default.
• W2013164041 hasBestOaLocation W20131640411 @default.

• next